JJH260 is an N-hydroxy hydantoin carbamate that inhibits androgen-induced gene 1 (AIG1), an enzyme that hydrolyzes fatty acid esters of hydroxy fatty acids (FAHFAs). It blocks the hydrolysis of 9-PAHSA with an IC50 value of 0.57 μM. JJH260 also inhibits the novel FAHFA hydrolase androgen-dependent TFPI-regulating protein (ADTRP; IC50 = 8.5 μM), as well as the serine hydrolase ABHD6 and the lysophospholipases LYPLA1 and LYPLA2. JJH260 inhibits the FAHFA hydrolase activity of LNCaP and T cell lysates and intact cells.

non-steroidal androgen receptor (AR) antagonist

Leelamine hydrochloride, a tricyclic diterpene extracted from pine tree bark, inhibits the transcriptional activity of the androgen receptor, known to regulate fatty acid synthesis [2,3]. This compound acts as a cannabinoid receptor type 1 (CB1) agonist and suppresses SREBP1-regulated fatty acid/lipid synthesis in prostate cancer cells, irrespective of androgen receptor status.

Androgen receptor degrader-1 (compound 18)作为高效的雄激素受体降解剂, 主要应用于癌症研究。

YXG-158（Compound 23-h）是具有口服活性的AR降解剂和CYP17A1抑制剂。该化合物的AR降解活性表现在其DC50值为1.28 μM，而对CYP17A1的抑制作用则体现在其IC50值为100 nM。YXG-158适用于研究恩杂鲁胺耐药性前列腺癌。

(1S,3R)-GNE-502 (compound 179) 是一种 Erα 的有效降解剂，能够在 MCF7 HCS 细胞中降解 ERα (EC50: 13 nM)。(1S,3R)-GNE-502 可以用于与雌激素受体相关癌症的研究。

GNE-274, a non-degrader compound structurally similar to GDC-0927 (an ER degrader), serves as a partial ER agonist in breast cancer cell lines without triggering ER turnover. Notably, GNE-274 enhances chromatin accessibility at ER-DNA binding sites, unlike GDC-0927. Acting as a potent inhibitor of the ER-ligand binding domain (LBD), GNE-274 exhibits potential for cancer research purposes.

DK1 是有效的雌激素相关受体调节剂。DK1 影响 ERRα 受体的活性，具有降低血糖的能力。DK1 显示出研究糖尿病的潜力。

FSHR agonist 1是一种对卵泡刺激素(FSH)受体(FSHR)具有高亲和力并能引起变构的激动剂，具有pEC50值为7.72。它通过与TMD广泛相互作用直接激活FSHR。